http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 11 Dec 2025 08:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Announces+Engagement+with+Shanghai-Based+YAFO+Capital/25726993.html <p>Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - BetterLife Pharma Inc.&#160;(CSE: BETR) (OTCQB: BETRF)&#160;(FSE: NPAU)&#160;("BetterLife" or the "Company"), an emerging biotech company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD"), is pleased to announce it has signed an engagement agreement with Shanghai-based YAFO Capital ("YAFO"), as its exclusive advisor to seek strategic partnerships for development of BETR-001 in the Greater China regions, including mainland China, Hong Kong, Taiwan and Macau. Pursuant to the agreement, BetterLife intends to retain YAFO on a non-exclusive basis for territories outside of Greater China.</p><p>Dr. Ahmad Doroudian, CEO http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Announces+Engagement+with+Shanghai-Based+YAFO+Capital/25726993.html Thu, 11 Dec 2025 08:00:00 -0500 BETRF http://www.streetinsider.com/Newsfile/BetterLife+Pharma+Announces+Engagement+with+Shanghai-Based+YAFO+Capital/25726993.html <p>Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - BetterLife Pharma Inc.&#160;(CSE: BETR) (OTCQB: BETRF)&#160;(FSE: NPAU)&#160;("BetterLife" or the "Company"), an emerging biotech company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD"), is pleased to announce it has signed an engagement agreement with Shanghai-based YAFO Capital ("YAFO"), as its exclusive advisor to seek strategic partnerships for development of BETR-001 in the Greater China regions, including mainland China, Hong Kong, Taiwan and Macau. Pursuant to the agreement, BetterLife intends to retain YAFO on a non-exclusive basis for territories outside of Greater China.</p><p>Dr. Ahmad Doroudian, CEO http://www.streetinsider.com/Newsfile/BetterLife+Pharma+Announces+Engagement+with+Shanghai-Based+YAFO+Capital/25726993.html Thu, 11 Dec 2025 08:00:00 -0500 BETRF http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Debt+Settlements/24750822.html <p align="justify">VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tcbSOusV72hKK4B7mvxwKrfzQlethbRVZdzjZpvZXqXIu9-KFjqUT_UZUrxxJmaqcwFTr9X-_JBkNN6eYvmfE9a3aX9ywPfoMDJP-Sc23Vm6yccvH0sLIeCSwGKvGZsLfdApEPoy-7T2Avsh0iCdWA==" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yUWXbno2EADQ-NNDFD_aOGtH0ziPDF2zkps-lCi_n6fdJYtteD6vJok_SmiMS00i7DiM4BWenhltW21QLeurh4Xt8sA6iAzW_gfK9-ZGTtM=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sQfo8bkfAPtgKCqx1QvOJTRZPT5uQsK-48cxKfuo3S6JsrCFoAnLQWQBF6JwZVRw-vn4bz9B4JIuFl0Xf71Dn_k5IcrkFXUNRVX6ok5a5Wswi5fOCO8e9uIjlWSaIsy6" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Debt+Settlements/24750822.html Tue, 06 May 2025 16:38:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Debt+Settlements/24750822.html <p align="justify">VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tcbSOusV72hKK4B7mvxwKrfzQlethbRVZdzjZpvZXqXIu9-KFjqUT_UZUrxxJmaqcwFTr9X-_JBkNN6eYvmfE9a3aX9ywPfoMDJP-Sc23Vm6yccvH0sLIeCSwGKvGZsLfdApEPoy-7T2Avsh0iCdWA==" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yUWXbno2EADQ-NNDFD_aOGtH0ziPDF2zkps-lCi_n6fdJYtteD6vJok_SmiMS00i7DiM4BWenhltW21QLeurh4Xt8sA6iAzW_gfK9-ZGTtM=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sQfo8bkfAPtgKCqx1QvOJTRZPT5uQsK-48cxKfuo3S6JsrCFoAnLQWQBF6JwZVRw-vn4bz9B4JIuFl0Xf71Dn_k5IcrkFXUNRVX6ok5a5Wswi5fOCO8e9uIjlWSaIsy6" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Debt+Settlements/24750822.html Tue, 06 May 2025 16:38:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Debt+Settlements/24750822.html <p align="justify">VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tcbSOusV72hKK4B7mvxwKrfzQlethbRVZdzjZpvZXqXIu9-KFjqUT_UZUrxxJmaqcwFTr9X-_JBkNN6eYvmfE9a3aX9ywPfoMDJP-Sc23Vm6yccvH0sLIeCSwGKvGZsLfdApEPoy-7T2Avsh0iCdWA==" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yUWXbno2EADQ-NNDFD_aOGtH0ziPDF2zkps-lCi_n6fdJYtteD6vJok_SmiMS00i7DiM4BWenhltW21QLeurh4Xt8sA6iAzW_gfK9-ZGTtM=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sQfo8bkfAPtgKCqx1QvOJTRZPT5uQsK-48cxKfuo3S6JsrCFoAnLQWQBF6JwZVRw-vn4bz9B4JIuFl0Xf71Dn_k5IcrkFXUNRVX6ok5a5Wswi5fOCO8e9uIjlWSaIsy6" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Debt+Settlements/24750822.html Tue, 06 May 2025 16:38:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Debt+Settlements/24750822.html <p align="justify">VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tcbSOusV72hKK4B7mvxwKrfzQlethbRVZdzjZpvZXqXIu9-KFjqUT_UZUrxxJmaqcwFTr9X-_JBkNN6eYvmfE9a3aX9ywPfoMDJP-Sc23Vm6yccvH0sLIeCSwGKvGZsLfdApEPoy-7T2Avsh0iCdWA==" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yUWXbno2EADQ-NNDFD_aOGtH0ziPDF2zkps-lCi_n6fdJYtteD6vJok_SmiMS00i7DiM4BWenhltW21QLeurh4Xt8sA6iAzW_gfK9-ZGTtM=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sQfo8bkfAPtgKCqx1QvOJTRZPT5uQsK-48cxKfuo3S6JsrCFoAnLQWQBF6JwZVRw-vn4bz9B4JIuFl0Xf71Dn_k5IcrkFXUNRVX6ok5a5Wswi5fOCO8e9uIjlWSaIsy6" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian http://www.streetinsider.com/Press+Releases/BetterLife+Announces+Debt+Settlements/24750822.html Tue, 06 May 2025 16:38:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/BetterLife+Announces+Debt+Settlements/24750822.html <p align="justify">VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tcbSOusV72hKK4B7mvxwKrfzQlethbRVZdzjZpvZXqXIu9-KFjqUT_UZUrxxJmaqcwFTr9X-_JBkNN6eYvmfE9a3aX9ywPfoMDJP-Sc23Vm6yccvH0sLIeCSwGKvGZsLfdApEPoy-7T2Avsh0iCdWA==" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yUWXbno2EADQ-NNDFD_aOGtH0ziPDF2zkps-lCi_n6fdJYtteD6vJok_SmiMS00i7DiM4BWenhltW21QLeurh4Xt8sA6iAzW_gfK9-ZGTtM=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sQfo8bkfAPtgKCqx1QvOJTRZPT5uQsK-48cxKfuo3S6JsrCFoAnLQWQBF6JwZVRw-vn4bz9B4JIuFl0Xf71Dn_k5IcrkFXUNRVX6ok5a5Wswi5fOCO8e9uIjlWSaIsy6" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian http://www.streetinsider.com/Globe+Newswire/BetterLife+Announces+Debt+Settlements/24750822.html Tue, 06 May 2025 16:38:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/BetterLife+Announces+Debt+Settlements/24750822.html <p align="justify">VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tcbSOusV72hKK4B7mvxwKrfzQlethbRVZdzjZpvZXqXIu9-KFjqUT_UZUrxxJmaqcwFTr9X-_JBkNN6eYvmfE9a3aX9ywPfoMDJP-Sc23Vm6yccvH0sLIeCSwGKvGZsLfdApEPoy-7T2Avsh0iCdWA==" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yUWXbno2EADQ-NNDFD_aOGtH0ziPDF2zkps-lCi_n6fdJYtteD6vJok_SmiMS00i7DiM4BWenhltW21QLeurh4Xt8sA6iAzW_gfK9-ZGTtM=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sQfo8bkfAPtgKCqx1QvOJTRZPT5uQsK-48cxKfuo3S6JsrCFoAnLQWQBF6JwZVRw-vn4bz9B4JIuFl0Xf71Dn_k5IcrkFXUNRVX6ok5a5Wswi5fOCO8e9uIjlWSaIsy6" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian http://www.streetinsider.com/Globe+Newswire/BetterLife+Announces+Debt+Settlements/24750822.html Tue, 06 May 2025 16:38:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/BetterLife+Announces+Debt+Settlements/24750822.html <p align="justify">VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tcbSOusV72hKK4B7mvxwKrfzQlethbRVZdzjZpvZXqXIu9-KFjqUT_UZUrxxJmaqcwFTr9X-_JBkNN6eYvmfE9a3aX9ywPfoMDJP-Sc23Vm6yccvH0sLIeCSwGKvGZsLfdApEPoy-7T2Avsh0iCdWA==" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yUWXbno2EADQ-NNDFD_aOGtH0ziPDF2zkps-lCi_n6fdJYtteD6vJok_SmiMS00i7DiM4BWenhltW21QLeurh4Xt8sA6iAzW_gfK9-ZGTtM=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sQfo8bkfAPtgKCqx1QvOJTRZPT5uQsK-48cxKfuo3S6JsrCFoAnLQWQBF6JwZVRw-vn4bz9B4JIuFl0Xf71Dn_k5IcrkFXUNRVX6ok5a5Wswi5fOCO8e9uIjlWSaIsy6" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian http://www.streetinsider.com/Globe+Newswire/BetterLife+Announces+Debt+Settlements/24750822.html Tue, 06 May 2025 16:38:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/BetterLife+Announces+Debt+Settlements/24750822.html <p align="justify">VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=tcbSOusV72hKK4B7mvxwKrfzQlethbRVZdzjZpvZXqXIu9-KFjqUT_UZUrxxJmaqcwFTr9X-_JBkNN6eYvmfE9a3aX9ywPfoMDJP-Sc23Vm6yccvH0sLIeCSwGKvGZsLfdApEPoy-7T2Avsh0iCdWA==" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yUWXbno2EADQ-NNDFD_aOGtH0ziPDF2zkps-lCi_n6fdJYtteD6vJok_SmiMS00i7DiM4BWenhltW21QLeurh4Xt8sA6iAzW_gfK9-ZGTtM=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sQfo8bkfAPtgKCqx1QvOJTRZPT5uQsK-48cxKfuo3S6JsrCFoAnLQWQBF6JwZVRw-vn4bz9B4JIuFl0Xf71Dn_k5IcrkFXUNRVX6ok5a5Wswi5fOCO8e9uIjlWSaIsy6" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders,   announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian http://www.streetinsider.com/Globe+Newswire/BetterLife+Announces+Debt+Settlements/24750822.html Tue, 06 May 2025 16:38:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html <p>VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0f0_bQCbBR9WC7aPx7vXsG5XFNCZyIaBzXBBwvBA4F46jAiXb4k94SnDgXp2CFirrOCM_cFja1Z--ZTNMG3XH4CZYFtrLnPaTb6sLbJ-X8CkbJSgNwPUFbJzRSut9xdb" rel="nofollow" target="_blank">CSE: BETR</a> / <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aKHREkPOrs1xvPIIu7foE3o9Qh7_0pcKH1odIc-PcswvxEtwOyvbxDdYg3maCaajjvRbMD5NmUfV2A3YLnheUSOFaDjA0mVrC_5evsQhjzedi6Y2W0BO-QlaS3EXIA2X" rel="nofollow" target="_blank">OTCQB : BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=L5gBT5idHzGzqYVjX03Aw8vMbRS39YTcIhtjvccg69u6wlKrXV6KoJpbILAs0Q2P1K_iI_cXqe9tnHxqCffeXkuQ9l3Otn_6Tya9XI4LknFlNH5KMIxudejm9o8snU1f" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.</p> <p align="justify">Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html Thu, 03 Apr 2025 08:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html <p>VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0f0_bQCbBR9WC7aPx7vXsG5XFNCZyIaBzXBBwvBA4F46jAiXb4k94SnDgXp2CFirrOCM_cFja1Z--ZTNMG3XH4CZYFtrLnPaTb6sLbJ-X8CkbJSgNwPUFbJzRSut9xdb" rel="nofollow" target="_blank">CSE: BETR</a> / <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aKHREkPOrs1xvPIIu7foE3o9Qh7_0pcKH1odIc-PcswvxEtwOyvbxDdYg3maCaajjvRbMD5NmUfV2A3YLnheUSOFaDjA0mVrC_5evsQhjzedi6Y2W0BO-QlaS3EXIA2X" rel="nofollow" target="_blank">OTCQB : BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=L5gBT5idHzGzqYVjX03Aw8vMbRS39YTcIhtjvccg69u6wlKrXV6KoJpbILAs0Q2P1K_iI_cXqe9tnHxqCffeXkuQ9l3Otn_6Tya9XI4LknFlNH5KMIxudejm9o8snU1f" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.</p> <p align="justify">Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html Thu, 03 Apr 2025 08:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html <p>VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0f0_bQCbBR9WC7aPx7vXsG5XFNCZyIaBzXBBwvBA4F46jAiXb4k94SnDgXp2CFirrOCM_cFja1Z--ZTNMG3XH4CZYFtrLnPaTb6sLbJ-X8CkbJSgNwPUFbJzRSut9xdb" rel="nofollow" target="_blank">CSE: BETR</a> / <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aKHREkPOrs1xvPIIu7foE3o9Qh7_0pcKH1odIc-PcswvxEtwOyvbxDdYg3maCaajjvRbMD5NmUfV2A3YLnheUSOFaDjA0mVrC_5evsQhjzedi6Y2W0BO-QlaS3EXIA2X" rel="nofollow" target="_blank">OTCQB : BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=L5gBT5idHzGzqYVjX03Aw8vMbRS39YTcIhtjvccg69u6wlKrXV6KoJpbILAs0Q2P1K_iI_cXqe9tnHxqCffeXkuQ9l3Otn_6Tya9XI4LknFlNH5KMIxudejm9o8snU1f" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.</p> <p align="justify">Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html Thu, 03 Apr 2025 08:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html <p>VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0f0_bQCbBR9WC7aPx7vXsG5XFNCZyIaBzXBBwvBA4F46jAiXb4k94SnDgXp2CFirrOCM_cFja1Z--ZTNMG3XH4CZYFtrLnPaTb6sLbJ-X8CkbJSgNwPUFbJzRSut9xdb" rel="nofollow" target="_blank">CSE: BETR</a> / <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aKHREkPOrs1xvPIIu7foE3o9Qh7_0pcKH1odIc-PcswvxEtwOyvbxDdYg3maCaajjvRbMD5NmUfV2A3YLnheUSOFaDjA0mVrC_5evsQhjzedi6Y2W0BO-QlaS3EXIA2X" rel="nofollow" target="_blank">OTCQB : BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=L5gBT5idHzGzqYVjX03Aw8vMbRS39YTcIhtjvccg69u6wlKrXV6KoJpbILAs0Q2P1K_iI_cXqe9tnHxqCffeXkuQ9l3Otn_6Tya9XI4LknFlNH5KMIxudejm9o8snU1f" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.</p> <p align="justify">Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, http://www.streetinsider.com/Press+Releases/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html Thu, 03 Apr 2025 08:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html <p>VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0f0_bQCbBR9WC7aPx7vXsG5XFNCZyIaBzXBBwvBA4F46jAiXb4k94SnDgXp2CFirrOCM_cFja1Z--ZTNMG3XH4CZYFtrLnPaTb6sLbJ-X8CkbJSgNwPUFbJzRSut9xdb" rel="nofollow" target="_blank">CSE: BETR</a> / <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aKHREkPOrs1xvPIIu7foE3o9Qh7_0pcKH1odIc-PcswvxEtwOyvbxDdYg3maCaajjvRbMD5NmUfV2A3YLnheUSOFaDjA0mVrC_5evsQhjzedi6Y2W0BO-QlaS3EXIA2X" rel="nofollow" target="_blank">OTCQB : BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=L5gBT5idHzGzqYVjX03Aw8vMbRS39YTcIhtjvccg69u6wlKrXV6KoJpbILAs0Q2P1K_iI_cXqe9tnHxqCffeXkuQ9l3Otn_6Tya9XI4LknFlNH5KMIxudejm9o8snU1f" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.</p> <p align="justify">Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, http://www.streetinsider.com/Globe+Newswire/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html Thu, 03 Apr 2025 08:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html <p>VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0f0_bQCbBR9WC7aPx7vXsG5XFNCZyIaBzXBBwvBA4F46jAiXb4k94SnDgXp2CFirrOCM_cFja1Z--ZTNMG3XH4CZYFtrLnPaTb6sLbJ-X8CkbJSgNwPUFbJzRSut9xdb" rel="nofollow" target="_blank">CSE: BETR</a> / <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aKHREkPOrs1xvPIIu7foE3o9Qh7_0pcKH1odIc-PcswvxEtwOyvbxDdYg3maCaajjvRbMD5NmUfV2A3YLnheUSOFaDjA0mVrC_5evsQhjzedi6Y2W0BO-QlaS3EXIA2X" rel="nofollow" target="_blank">OTCQB : BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=L5gBT5idHzGzqYVjX03Aw8vMbRS39YTcIhtjvccg69u6wlKrXV6KoJpbILAs0Q2P1K_iI_cXqe9tnHxqCffeXkuQ9l3Otn_6Tya9XI4LknFlNH5KMIxudejm9o8snU1f" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.</p> <p align="justify">Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, http://www.streetinsider.com/Globe+Newswire/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html Thu, 03 Apr 2025 08:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html <p>VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0f0_bQCbBR9WC7aPx7vXsG5XFNCZyIaBzXBBwvBA4F46jAiXb4k94SnDgXp2CFirrOCM_cFja1Z--ZTNMG3XH4CZYFtrLnPaTb6sLbJ-X8CkbJSgNwPUFbJzRSut9xdb" rel="nofollow" target="_blank">CSE: BETR</a> / <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aKHREkPOrs1xvPIIu7foE3o9Qh7_0pcKH1odIc-PcswvxEtwOyvbxDdYg3maCaajjvRbMD5NmUfV2A3YLnheUSOFaDjA0mVrC_5evsQhjzedi6Y2W0BO-QlaS3EXIA2X" rel="nofollow" target="_blank">OTCQB : BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=L5gBT5idHzGzqYVjX03Aw8vMbRS39YTcIhtjvccg69u6wlKrXV6KoJpbILAs0Q2P1K_iI_cXqe9tnHxqCffeXkuQ9l3Otn_6Tya9XI4LknFlNH5KMIxudejm9o8snU1f" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.</p> <p align="justify">Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, http://www.streetinsider.com/Globe+Newswire/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html Thu, 03 Apr 2025 08:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html <p>VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=0f0_bQCbBR9WC7aPx7vXsG5XFNCZyIaBzXBBwvBA4F46jAiXb4k94SnDgXp2CFirrOCM_cFja1Z--ZTNMG3XH4CZYFtrLnPaTb6sLbJ-X8CkbJSgNwPUFbJzRSut9xdb" rel="nofollow" target="_blank">CSE: BETR</a> / <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aKHREkPOrs1xvPIIu7foE3o9Qh7_0pcKH1odIc-PcswvxEtwOyvbxDdYg3maCaajjvRbMD5NmUfV2A3YLnheUSOFaDjA0mVrC_5evsQhjzedi6Y2W0BO-QlaS3EXIA2X" rel="nofollow" target="_blank">OTCQB : BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=L5gBT5idHzGzqYVjX03Aw8vMbRS39YTcIhtjvccg69u6wlKrXV6KoJpbILAs0Q2P1K_iI_cXqe9tnHxqCffeXkuQ9l3Otn_6Tya9XI4LknFlNH5KMIxudejm9o8snU1f" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company, has announced that it has appointed André Beaudry as Corporate Advisor. Mr. Beaudry has over 30 years of experience in the areas of fundraising, government relations, national and international program management, as well as governance.</p> <p align="justify">Mr. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, http://www.streetinsider.com/Globe+Newswire/BetterLife+Pharma+Appoints+Corporate+Advisor/24594717.html Thu, 03 Apr 2025 08:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html <p align="justify">VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pvkcJkvvtpynv9wu8j0ZVeV5fBPK3L0voY2mW9JAMeEfacbVS7PB_18STvUMOcu7znklduQKexKWoawI8WH2SRezVUfrzMSxlrXv6CKIdIb919_4gZDFMIaN9Ba8bTY7" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Knpg4KGB_ZvotlFKdqE3VVqEiZ7Izfw2zv6Nxc5pMnUegF-_v6O5fGaBiPTcQEjmfW7bF-nUsM_4TWeaNa3Z9MqBykb-WKZinsZR11U2BW0=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=c5DB9103egOEZr4RJB67HIK7ENijMcYuYSNHXiJX9nc14NORfOdErGTOKX9UfR1ErB7FO5xk2wR1zFLqtouRixctTaMBYEWmwy8Bx5gWGNC8n8iGUi6YLSOTHKeBZfuc" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian:<br/></p> <table http://www.streetinsider.com/Press+Releases/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html Tue, 16 Jul 2024 18:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html <p align="justify">VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pvkcJkvvtpynv9wu8j0ZVeV5fBPK3L0voY2mW9JAMeEfacbVS7PB_18STvUMOcu7znklduQKexKWoawI8WH2SRezVUfrzMSxlrXv6CKIdIb919_4gZDFMIaN9Ba8bTY7" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Knpg4KGB_ZvotlFKdqE3VVqEiZ7Izfw2zv6Nxc5pMnUegF-_v6O5fGaBiPTcQEjmfW7bF-nUsM_4TWeaNa3Z9MqBykb-WKZinsZR11U2BW0=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=c5DB9103egOEZr4RJB67HIK7ENijMcYuYSNHXiJX9nc14NORfOdErGTOKX9UfR1ErB7FO5xk2wR1zFLqtouRixctTaMBYEWmwy8Bx5gWGNC8n8iGUi6YLSOTHKeBZfuc" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian:<br/></p> <table http://www.streetinsider.com/Press+Releases/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html Tue, 16 Jul 2024 18:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html <p align="justify">VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pvkcJkvvtpynv9wu8j0ZVeV5fBPK3L0voY2mW9JAMeEfacbVS7PB_18STvUMOcu7znklduQKexKWoawI8WH2SRezVUfrzMSxlrXv6CKIdIb919_4gZDFMIaN9Ba8bTY7" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Knpg4KGB_ZvotlFKdqE3VVqEiZ7Izfw2zv6Nxc5pMnUegF-_v6O5fGaBiPTcQEjmfW7bF-nUsM_4TWeaNa3Z9MqBykb-WKZinsZR11U2BW0=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=c5DB9103egOEZr4RJB67HIK7ENijMcYuYSNHXiJX9nc14NORfOdErGTOKX9UfR1ErB7FO5xk2wR1zFLqtouRixctTaMBYEWmwy8Bx5gWGNC8n8iGUi6YLSOTHKeBZfuc" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian:<br/></p> <table http://www.streetinsider.com/Press+Releases/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html Tue, 16 Jul 2024 18:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Press+Releases/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html <p align="justify">VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pvkcJkvvtpynv9wu8j0ZVeV5fBPK3L0voY2mW9JAMeEfacbVS7PB_18STvUMOcu7znklduQKexKWoawI8WH2SRezVUfrzMSxlrXv6CKIdIb919_4gZDFMIaN9Ba8bTY7" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Knpg4KGB_ZvotlFKdqE3VVqEiZ7Izfw2zv6Nxc5pMnUegF-_v6O5fGaBiPTcQEjmfW7bF-nUsM_4TWeaNa3Z9MqBykb-WKZinsZR11U2BW0=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=c5DB9103egOEZr4RJB67HIK7ENijMcYuYSNHXiJX9nc14NORfOdErGTOKX9UfR1ErB7FO5xk2wR1zFLqtouRixctTaMBYEWmwy8Bx5gWGNC8n8iGUi6YLSOTHKeBZfuc" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian:<br/></p> <table http://www.streetinsider.com/Press+Releases/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html Tue, 16 Jul 2024 18:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html <p align="justify">VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pvkcJkvvtpynv9wu8j0ZVeV5fBPK3L0voY2mW9JAMeEfacbVS7PB_18STvUMOcu7znklduQKexKWoawI8WH2SRezVUfrzMSxlrXv6CKIdIb919_4gZDFMIaN9Ba8bTY7" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Knpg4KGB_ZvotlFKdqE3VVqEiZ7Izfw2zv6Nxc5pMnUegF-_v6O5fGaBiPTcQEjmfW7bF-nUsM_4TWeaNa3Z9MqBykb-WKZinsZR11U2BW0=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=c5DB9103egOEZr4RJB67HIK7ENijMcYuYSNHXiJX9nc14NORfOdErGTOKX9UfR1ErB7FO5xk2wR1zFLqtouRixctTaMBYEWmwy8Bx5gWGNC8n8iGUi6YLSOTHKeBZfuc" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian:<br/></p> <table http://www.streetinsider.com/Globe+Newswire/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html Tue, 16 Jul 2024 18:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html <p align="justify">VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pvkcJkvvtpynv9wu8j0ZVeV5fBPK3L0voY2mW9JAMeEfacbVS7PB_18STvUMOcu7znklduQKexKWoawI8WH2SRezVUfrzMSxlrXv6CKIdIb919_4gZDFMIaN9Ba8bTY7" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Knpg4KGB_ZvotlFKdqE3VVqEiZ7Izfw2zv6Nxc5pMnUegF-_v6O5fGaBiPTcQEjmfW7bF-nUsM_4TWeaNa3Z9MqBykb-WKZinsZR11U2BW0=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=c5DB9103egOEZr4RJB67HIK7ENijMcYuYSNHXiJX9nc14NORfOdErGTOKX9UfR1ErB7FO5xk2wR1zFLqtouRixctTaMBYEWmwy8Bx5gWGNC8n8iGUi6YLSOTHKeBZfuc" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian:<br/></p> <table http://www.streetinsider.com/Globe+Newswire/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html Tue, 16 Jul 2024 18:00:00 -0500 BETR BETRF NPAU O.08486314 http://www.streetinsider.com/Globe+Newswire/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html <p align="justify">VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pvkcJkvvtpynv9wu8j0ZVeV5fBPK3L0voY2mW9JAMeEfacbVS7PB_18STvUMOcu7znklduQKexKWoawI8WH2SRezVUfrzMSxlrXv6CKIdIb919_4gZDFMIaN9Ba8bTY7" rel="nofollow" target="_blank">BETR</a> / OTCQB: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Knpg4KGB_ZvotlFKdqE3VVqEiZ7Izfw2zv6Nxc5pMnUegF-_v6O5fGaBiPTcQEjmfW7bF-nUsM_4TWeaNa3Z9MqBykb-WKZinsZR11U2BW0=" rel="nofollow" target="_blank">BETRF</a> / FRA: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=c5DB9103egOEZr4RJB67HIK7ENijMcYuYSNHXiJX9nc14NORfOdErGTOKX9UfR1ErB7FO5xk2wR1zFLqtouRixctTaMBYEWmwy8Bx5gWGNC8n8iGUi6YLSOTHKeBZfuc" rel="nofollow" target="_blank">NPAU</a>), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian:<br/></p> <table http://www.streetinsider.com/Globe+Newswire/Amendment+of+Disclosures+in+Past+Management+Information+Circulars/23470720.html Tue, 16 Jul 2024 18:00:00 -0500 BETR BETRF NPAU O.08486314